Apixaban: A review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery

Drugs

Volumn 72, Issue 9, 2012, Pages 1271-1291

  Deeks, Emma D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Anticoagulants; Apixaban; Deep vein thrombosis; Factor Xa inhibitors; Pharmacokinetics; Pharmacology; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A INHIBITOR; BMS 593214; CARBAMAZEPINE; CLOPIDOGREL; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; HEPARIN; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; NAPROXEN; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ANEMIA; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; BLOOD CLOTTING TIME; CONSTIPATION; CONTUSION; DEEP VEIN THROMBOSIS; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; HEART INFARCTION; HIP ARTHROPLASTY; HUMAN; HYPOTENSION; INFECTION; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; KNEE ARTHROPLASTY; LIVER INJURY; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHUNT THROMBOSIS; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; VOMITING;

ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; FIBRINOLYTIC AGENTS; HUMANS; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 84862120801     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209020-000000000-00000     Document Type: Review

References (72)

1. Previtali E, Bucciarelli P, Passamonti SM, et al. Risk factors for venous and arterial thrombosis. Blood Transfus 2011 Apr; 9 (2): 120-38
2. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005 Aug; 3 (8): 1611-7 (Pubitemid 41716546)
3. Deitelzweig SB, McKean SC, Amin AN, et al. Prevention of venous thromboembolism in the orthopedic surgery patient. Cleve Clin J Med 2008 Apr; 75 Suppl. 3: S27-36
4. Heit JA. Estimating the incidence of symptomatic postoperative venous thromboembolism: the importance of perspective. JAMA 2012 Jan 18; 307 (3): 306-7
5. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global OrthopaedicRegistry. J Bone Joint Surg Br 2007 Jun; 89-B (6): 799-807 (Pubitemid 47180202)
6. Kearon C. Natural history of venous thromboembolism. Circulation 2003 Jun 17; 107 (23 Suppl. 1): I22-30 (Pubitemid 41289268)
7. Imberti D, Prisco D. Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review. PathophysiolHaemost Thromb 2008; 36 (5): 217-26
8. Schulman S, Majeed A. A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. Drug Saf 2011; 34 (6): 449-63
9. Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011 Jul; 9 Suppl. 1: 12-9
10. Nutescu EA, Shapiro NL, Chevalier A, et al. A pharmacologic overview of current and emerging anticoagulants. Cleve Clin J Med 2005 Apr; 72 Suppl. 1: S2-6
11. Eikelboom JW, Zelenkofske SL, Rusconi CP. Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol 2010 Mar; 30 (3): 382-7
12. Prom R, Spinler SA. The role of apixaban for venous and arterial thromboembolic disease. Ann Pharmacother 2011 Oct; 45 (10): 1262-83
13. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008 Feb; 34 (1): 39-57 (Pubitemid 351640881)
14. Wang L, Raghavan N, He K, et al. Sulfation of O-demethyl apixaban: enzyme identification and species comparison. Drug Met Dispos 2009 Apr; 37 (4): 802-8
15. Wong PC, Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost 2010 Aug; 104 (2): 302-10
16. Jiang X, Crain EJ, Luettgen JM, et al. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro [letter]. Thromb Haemost 2009 Apr; 101 (4): 780-2
17. Luettgen JM, Knabb RM, He K, et al. Apixaban inhibition of factor Xa: microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. J Enzyme Inhib Med Chem 2011 Aug; 26 (4): 514-26
18. Pinto DJP, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7- oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007 Nov 1; 50 (22): 5339-56 (Pubitemid 350057846)
19. Schumacher WA, Bostwick JS, Stewart AB, et al. Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis. J Cardiovasc Pharmacol 2010 Jun; 55 (6): 609-16
20. Wong PC, Crain EJ, Watson CA, et al. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost 2009 Aug; 7 (8): 1313-20
21. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008 May; 6 (5): 820-9 (Pubitemid 351524543)
22. Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost 2008 Oct; 6 (10): 1736-41
23. Wong P, Watson C, Knabb R, et al. The combination of apixaban, a direct factor Xa inhibitor, with heparin or enoxaparin in rabbits elicits additive antithrombotic effects, with low bleeding [abstract no. 933]. Eur Heart J 2008 Sep; 29 Suppl. 1: 133-4
24. Becker RC, Alexander JH, Newby LK, et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost 2010 Nov; 104 (5): 976-83
25. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010 Dec; 104 (6): 1263-71
26. Barrett YC, Wang J, Knabb R, et al. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thromb Haemost 2011 Jan; 105 (1): 181-9
27. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome.NEngl J Med 2011 Aug 25; 365 (8): 699-708
28. Frost C, Song Y, Barrett YC, et al. Direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [abstract no. P-WE-159]. J Thromb Haemost 2011 Jul; 9 Suppl. 2: 569-70
29. Bristol-Myers Squibb/Pfizer EEIG. Eliquis 2.5 mg filmcoated tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002148/WC500107728.pdf [Accessed 2012 May 29]
30. European Medicines Agency. Assessment report for Eliquis [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Public-assessment-report/human/002148/WC500107726.pdf [Accessed 2012 May 29]
31. Wong PC, Pinto DJP, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 2011 May; 31 (4): 478-92
32. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48 (1): 1-22
33. Frost CE, Nepal S, Barrett Y, et al. Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban [abstract no. PP-MO-407]. J Thromb Haemost 2009 Jul; 7 Suppl. 2: 455
34. Upreti VV, Wang J, Barrett Y, et al. Effect of body weight on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor, in healthy subjects [abstract no. 16]. J Clin Pharmacol 2010; 50: 1060
35. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009 Jan; 37 (1): 74-81
36. Frost C, Yu Z, Moore K, et al. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects [abstract no. P-M-664]. J Thromb Haemost 2007 Aug; 5 Suppl. 2
37. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010 Mar; 38 (3): 448-58
38. Zhang D, He K, Raghavan N, et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos 2009 Aug; 37 (8): 1738-48
39. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007 Dec; 5 (12): 2368-75 (Pubitemid 350154345)
40. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009 Aug 6; 361 (6): 594-604
41. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010 Mar 6; 375 (9717): 807-15
42. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010 Dec 23; 363 (26): 2487-98
43. Raskob GE, Gallus AS, Pineo GF, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 2012 Feb; 94-B (2): 257-64
44. Pineo GF, Gallus A, Raskob G, et al. Apixaban vs. enoxaparin after knee or hip surgery: efficacy and safety in key clinical subgroups [abstract no. O-TH-031]. J Thromb Haemost 2011; 9 Suppl. 2: 730-1
45. Huang J, Cao Y, Liao C, et al. Apixaban versus enoxaparin in patients with total knee arthroplasty: a meta-analysis of randomised trials. Thromb Haemost 2011 Feb 1; 105 (2): 245-53
46. Department of Health. Report of the independent expert working group on the prevention of venous thromboembolism in hospitalised patients [online]. Available from URL: http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/ documents/digitalasset/dh-073950.pdf [Accessed 2012 Jan 13]
47. Baser O. Prevalence and economic burden of venous thromboembolism after total hip arthroplasty or total knee arthroplasty. Am J Manag Care 2011 Feb; 17 (1 Suppl.): S6-8
48. National Institute for Health and Clinical Excellence. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/12695/47920/47920.pdf [Accessed 2011 Dec 23]
49. American Academy of Orthopaedic Surgeons. Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty: evidence-based guideline and evidence report [online]. Available from URL: http://www.aaos.org/Research/guidelines/VTE/VTE-full-guideline.pdf [Accessed 2011 Dec 23]
50. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012 Feb; 141 (2 Suppl.): e278S-325S
51. Abad Rico JI, Llau Pitarch JV, Páramo Ferná ndez JA. Topical issues in venous thromboembolism. Drugs 2010; 70 Suppl. 2: 11-8
52. Glaxo Group Ltd. Arixtra solution for injection, pre-filled syringe: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000403/WC500027746.pdf [Accessed 2012 May 29]
53. Sweetman SC. Martindale thirty-sixth edition: the complete drug reference. London and Chicago: Pharmaceutical Press, 2009
54. Wilke T, Mü ller S. Nonadherence in outpatient thromboprophylaxis after major orthopedic surgery: a systematic review. Expert Rev Pharmacoecon Outcomes Res 2010 Dec; 10 (6): 691-700
55. Bayer Schering Pharma AG. Xarelto film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000944/WC500057108.pdf [Accessed 2012 May 29]
56. Boehringer Ingelheim International GmbH. Pradaxa hard capsules: summary of product characteristics [online]. Available from URL: http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/000829/ WC500041059.pdf [Accessed 2012 May 29]
57. Friedman RJ. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials. Orthopedics 2011 Oct; 34 (10): 795-804
58. Wittkowsky AK. Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy 2011Dec; 31 (12): 1175-91
59. Rupprecht HJ, Blank R. Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs 2010 Nov 12; 70 (16): 2153-70
60. Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010 Jan; 103 (1): 62-70
61. Van Es J, Eerenberg ES, Kamphuisen PW, et al. How to prevent, treat, and overcome current clinical challenges of VTE. J Thromb Haemost 2011 Jul; 9 Suppl. 1: 265-74
62. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008 Mar; 28 (3): 380-6
63. National Institute for Health and Clinical Excellence. Final appraisal determination: apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults [online]. Available from URL: http://www. nice.org.uk/nicemedia/live/12795/57280/57280.pdf [Accessed 2012 Jan 18]
64. Janssen Pharmaceuticals, Inc. Xarelto (rivaroxaban) tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/202439s001lbl.pdf [Accessed 2012 May 29]
65. Duggan ST, Scott LJ, Plosker GL. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs 2009; 69 (13): 1829-51
66. Huo MH. New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: are they really better? Thromb Haemost 2011 Jul; 106 (1): 45-57
67. Watson J, Whiteside G, Perry C. Apixaban: first global approval. Drugs 2011 Oct 22; 71 (15): 2079-89
68. Maratea D, Fadda V, Trippoli S, et al. Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. J Thromb Haemost 2011 Sep; 9 (9): 1868-70
69. Mantha S. Oral factor Xa inhibitors vs. enoxaparin for thromboprophylaxis after joint replacement surgery: a metaanalysis [abstract no. P-MO-419]. J Thromb Haemost 2011; 9 Suppl. 2: 189
70. Gó mez-Outes A, Terleira-Ferná ndez A, Suá rez-Gea ML, et al. New oral anticoagulants for thromboprophylaxis after total hip or knee replacement: a meta-analysis and indirect treatment comparisons [abstract no. 08]. Basic Clin Pharmacol Toxicol 2011; 109 Suppl. 3: 34
71. Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ 2011; 14 (1): 65-74
72. Migliaccio-Walle K, Rublee D, Simon TA. Anticoagulation prophylaxis in orthopedic surgery: an efficacy frontier approach. Postgrad Med 2012 Jan; 124 (1): 41-9